A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will compare the efficacy of 100 days of Valcyte (900mg po daily)
prophylaxis with that of no prophylaxis, under the condition of pre-emptive therapy of active
CMV infection, in CMV positive renal transplant recipients. The influence of the two
prevention concepts on the occurrence of direct and indirect effects of active CMV infections
will be compared. The anticipated time on study treatment is 3 months-1 year, and the target
sample size is 100-500 individuals.